Which has stronger earnings and valuation, CING or PSTV?

Cingulate is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$3.59 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Is CING or PSTV more profitable?

Cingulate has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -238.40% -128.67% Plus Therapeutics -230.24% -198.48% -73.13%

Which has higher valuation & earnings, PSTV or TENX?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A

Do analysts prefer NTRB or PSTV?

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,449.26%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, PSTV or LONA?

Athira Pharma is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Athira Pharma N/A N/A -$105.61M -$4.21 N/A

Plus Therapeutics (PSTV) Competitors

$2.03 0.00 (0.00%)

As of 09/18/2026

Compare

PSTV vs. CING, TENX, NTRB, LONA, and SPRO

Should you buy Plus Therapeutics stock or one of its competitors? Plus Therapeutics's main competitors and comparable companies include Cingulate (CING), Tenax Therapeutics (TENX), Nutriband (NTRB), Athira Pharma (LONA), and Spero Therapeutics (SPRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Plus Therapeutics compare to Cingulate?

Cingulate (NASDAQ:CING) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Cingulate presently has a consensus target price of $27.00, indicating a potential upside of 415.27%. Plus Therapeutics has a consensus target price of $51.75, indicating a potential upside of 2,449.26%. Given Plus Therapeutics' higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cingulate has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

41.3% of Cingulate shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cingulate had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for Plus Therapeutics. Cingulate's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cingulate	Neutral
Plus Therapeutics	Neutral

Cingulate has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Cingulate is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Summary

Plus Therapeutics beats Cingulate on 7 of the 12 factors compared between the two stocks.

How does Plus Therapeutics compare to Tenax Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Tenax Therapeutics' return on equity of -61.54% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Tenax Therapeutics	N/A	-61.54%	-57.42%

In the previous week, Tenax Therapeutics had 9 more articles in the media than Plus Therapeutics. MarketBeat recorded 9 mentions for Tenax Therapeutics and 0 mentions for Plus Therapeutics. Tenax Therapeutics' average media sentiment score of 1.51 beat Plus Therapeutics' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Tenax Therapeutics	Very Positive

Plus Therapeutics presently has a consensus target price of $51.75, indicating a potential upside of 2,449.26%. Tenax Therapeutics has a consensus target price of $14.00, indicating a potential upside of 636.84%. Given Plus Therapeutics' higher possible upside, equities analysts clearly believe Plus Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Summary

Tenax Therapeutics beats Plus Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Nutriband's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nutriband	Neutral
Plus Therapeutics	Neutral

Nutriband has higher revenue and earnings than Plus Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	48.46	-$8.23M	-$0.53	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Nutriband has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Plus Therapeutics has a net margin of -230.24% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,449.26%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nutriband beats Plus Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Plus Therapeutics compare to Athira Pharma?

Plus Therapeutics (NASDAQ:PSTV) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Plus Therapeutics currently has a consensus price target of $51.75, suggesting a potential upside of 2,449.26%. Athira Pharma has a consensus price target of $17.33, suggesting a potential upside of 155.28%. Given Plus Therapeutics' higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Athira Pharma has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Athira Pharma	N/A	-411.58%	-225.73%

Athira Pharma is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

In the previous week, Plus Therapeutics' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Athira Pharma	Neutral

Summary

Plus Therapeutics and Athira Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Plus Therapeutics compare to Spero Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Spero Therapeutics has a net margin of 24.90% compared to Plus Therapeutics' net margin of -230.24%. Spero Therapeutics' return on equity of 16.17% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Spero Therapeutics	24.90%	16.17%	12.57%

Spero Therapeutics has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Spero Therapeutics	$66.80M	0.99	$8.57M	$0.11	10.27

Plus Therapeutics presently has a consensus target price of $51.75, suggesting a potential upside of 2,449.26%. Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 430.97%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Plus Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Spero Therapeutics had 10 more articles in the media than Plus Therapeutics. MarketBeat recorded 10 mentions for Spero Therapeutics and 0 mentions for Plus Therapeutics. Spero Therapeutics' average media sentiment score of 1.16 beat Plus Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Spero Therapeutics	Positive

Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats Plus Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.98M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.88	797.25	275.49	25.40
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	2.82	10.53	10.46	6.33
Net Income	-$22.39M	$2.82B	$3.49B	$358.33M
7 Day Performance	-12.69%	1.69%	0.59%	1.12%
1 Month Performance	-36.36%	0.24%	-1.74%	-2.39%
1 Year Performance	-80.46%	3.95%	18.13%	5.35%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	1.4191 of 5 stars	$2.03 flat	$51.75 +2,449.3%	-80.5%	$13.98M	N/A	N/A	20
CING Cingulate	2.1446 of 5 stars	$5.10 flat	$27.00 +429.4%	+48.0%	$74.16M	N/A	N/A	20	News Coverage Analyst Upgrade
TENX Tenax Therapeutics	4.0437 of 5 stars	$1.94 flat	$14.00 +621.6%	-70.4%	$72.60M	N/A	N/A	9	Positive News Insider Trade Short Interest Increase Gap Up
NTRB Nutriband	0.3387 of 5 stars	$5.97 flat	N/A	+12.6%	$72.57M	$2.04M	N/A	10	High Trading Volume
LONA Athira Pharma	2.3521 of 5 stars	$7.56 flat	$17.33 +129.3%	N/A	$71.01M	N/A	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. CING, TENX, NTRB, LONA, and SPRO

How does Plus Therapeutics compare to Cingulate?

Summary

How does Plus Therapeutics compare to Tenax Therapeutics?

Summary

How does Plus Therapeutics compare to Nutriband?

Summary

How does Plus Therapeutics compare to Athira Pharma?

Summary

How does Plus Therapeutics compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. CING, TENX, NTRB, LONA, and SPRO

How does Plus Therapeutics compare to Cingulate?

Do analysts recommend CING or PSTV?

Is CING or PSTV more profitable?

Do insiders & institutionals hold more shares of CING or PSTV?

Does the media prefer CING or PSTV?

Which has more risk & volatility, CING or PSTV?

Which has stronger earnings and valuation, CING or PSTV?

Summary

How does Plus Therapeutics compare to Tenax Therapeutics?

Do institutionals & insiders hold more shares of PSTV or TENX?

Which has more volatility and risk, PSTV or TENX?

Is PSTV or TENX more profitable?

Does the media prefer PSTV or TENX?

Do analysts recommend PSTV or TENX?

Which has higher valuation & earnings, PSTV or TENX?

Summary

How does Plus Therapeutics compare to Nutriband?

Does the media refer more to NTRB or PSTV?

Which has stronger valuation and earnings, NTRB or PSTV?

Which has more volatility and risk, NTRB or PSTV?

Is NTRB or PSTV more profitable?

Do analysts prefer NTRB or PSTV?

Do insiders & institutionals hold more shares of NTRB or PSTV?

Summary

How does Plus Therapeutics compare to Athira Pharma?

Do institutionals & insiders hold more shares of PSTV or LONA?

Do analysts prefer PSTV or LONA?

Is PSTV or LONA more profitable?

Which has higher valuation & earnings, PSTV or LONA?

Which has more risk and volatility, PSTV or LONA?

Does the media refer more to PSTV or LONA?

Summary

How does Plus Therapeutics compare to Spero Therapeutics?

Is PSTV or SPRO more profitable?

Which has preferable earnings and valuation, PSTV or SPRO?

Do analysts rate PSTV or SPRO?

Does the media refer more to PSTV or SPRO?

Which has more volatility and risk, PSTV or SPRO?

Do institutionals and insiders believe in PSTV or SPRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools